| abstract |
Disclosed herein are methods and compositions related to determining one or more biomarkers in Full-Length Excised Linear Intron RNAs (FLEXI RNAs) and Intron RNA fragments. These FLEXI RNAs and Intron RNA fragments can be indicative of a specific characteristic, trait, disease, disorder or condition. FLEXI RNAs and Intron RNA fragments can be used to establish a predictive biomarker, a diagnostic biomarker, a prognostic biomarker, or a biomarker that relates to drug interaction, drug response, or to a heritable condition. These biomarkers can then be used to treat, monitor, or inform patients. |